AbbVie Lifts Forecast and Defends Skyrizi After Rivals Loom

AbbVie Inc. raised its full-year profit forecast after quarterly results beat estimates, a sign of confidence amid growing competition for its superstar drug Skyrizi.

The North Chicago-based drugmaker now expects 2026 adjusted earnings of as much as $14.28 a share, a 12 cent increase that comes in ahead of the average midpoint estimate from analysts. First-quarter adjusted earnings of $2.65 a share outpaced Wall Street estimates of $2.60 a share, while revenue rose to $15 billion, also a beat.